• SmartestCrowd
    • No organizations
    • No projects
0
0
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, pha - The Lancet
2/17/23 at 11:32pm
Organization
The Lancet
82 words
0
Comments
ZF2001 is safe, well tolerated, and immunogenic in children and adolescents aged 3–17 years. Vaccine-elicited sera can neutralise the omicron BA.2 subvariant, but with reduced activity. The results support further studies of ZF2001 in children and adolescents.
You are the first to view
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00376-5/fulltext
Create an account or login to join the discussion